Clinical trials: Depressive Episodes
Bipolar Disorder
BHV-7000 Acute Treatment of Bipolar Mania
The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.
- Trial name
- NCT06419582
- Testing
- BHV-7000
- Where
- 32 sites in United States
- Volunteers
- 274 people
- Sponsor
- Biohaven Therapeutics Ltd.
Major Depressive Disorders
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive…
- Trial name
- NCT00825019
- Testing
- amibegron (SR58611A), paroxetine
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- Sanofi
Major Depressive Disorder
An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients
The primary objective of this study is to evaluate the efficacy of 3 fixed doses of SSR411298 (10, 50 or 200 mg daily) compared to placebo, in elderly patients with Major Depressive Disorder (MDD), based on the 17-item Hamilton…
- Trial name
- FIDELIO (NCT00822744)
- Testing
- SSR411298, Escitalopram
- Where
- 7 sites in Chile, Mexico and 5 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Depressive Disorder, Major
Alpha-Stim AID and Major Depressive Disorder
The study will be a multi-centre parallel group, double blind, non-commercial, randomised controlled superiority trial. Study participants will be referred from Primary Care GP practices via their GP and randomised into active…
- Trial name
- NCT04963907
- Testing
- Active Alpha-Stim CES
- Where
- United Kingdom
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Electromedical Products International, Inc.
Depression, Bipolar I Disorder
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States.
- Trial name
- 3112 Ped BPD (NCT04777357)
- Testing
- Cariprazine
- Where
- 81 sites in United States, Puerto Rico and 1 more
- Volunteers
- 380 people
- Sponsor
- AbbVie
Depressive Disorder, Major
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD-1 (NCT07412756)
- Testing
- Brenipatide
- Where
- 181 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Mood Disorder (Depressive Episodes)
Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes
Mood disorders like depression and bipolar disorder are widespread and cause serious psychological, cognitive, and social impairments, with a high burden on healthcare systems.
- Trial name
- EC-102 (NCT07087353)
- Testing
- Edra PRO
- Where
- 6 sites in France
- Volunteers
- 594 people
- Sponsor
- Resilience
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depressive Disorder, Major Depressive Disorder
Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder
This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks.
- Conditions
- Depressive Disorder, Major Depressive Disorder, Depressive Episode
- Trial name
- NCT05701345
- Testing
- OMNIFIT DTx-MDD, standard treatment
- Where
- 5 sites in South Korea
- Volunteers
- 162 people
- Sponsor
- Omni C&S
Depressive Disorder, Major, Depression
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
Evidence exists supporting the ability of genetic variations to influence patient drug response and side effects. Previous studies utilizing an open-label design have shown significant improvement in major depressive disorder…
- Conditions
- Depressive Disorder, Major, Depression, Depressive Disorder
- Trial name
- NCT02466477
- Testing
- GeneSight Psychotropic (GEN), Enhanced-GeneSight Psychotropic (E-GEN), Treatment as Usual (TAU)
- Where
- 14 sites in Canada
- Volunteers
- 542 people
- Sponsor
- Assurex Health Inc.
Bipolar Disorder
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.
- Trial name
- NCT00338273
- Testing
- Aripiprazole
- Where
- 8 sites in United States, India
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder, Elderly
Long-term Study of FK949E in Elderly Bipolar Disorder Patients
FK949E was administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an open-label manner.
- Trial name
- NCT01737268
- Testing
- FK949E
- Where
- 32 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Inc
Moderate Depressive Episodes (Major Depression)
Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes
The researchers in this trial want to learn more about the drug Laif® 900 in preventing the return of signs and symptoms of depressions (also called relapse) in patients suffering from moderate depression episodes.
- Trial name
- NCT04315597
- Testing
- Laif® 900, BAY98-7108
- Volunteers
- 398 people
- Sponsor
- Bayer
Depressive Disorders, Psychotic Disorders
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized…
- Conditions
- Depressive Disorders, Psychotic Disorders, Depression
- Trial name
- NCT00844922
- Testing
- SCH 900636
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Bipolar I Disorder
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
The purpose of this study is to evaluate several doses of aripiprazole in patients with bipolar depression.
- Trial name
- NCT00094432
- Testing
- Aripiprazole
- Where
- 40 sites in United States
- Volunteers
- 650 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar Disorders
A NIS Evaluating the Treatment Patterns of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder
The purpose of this NIS is to obtain data on how AAPs are used in DSM-IV-TR Bipolar I and II Disorder, in the course of a major depressive episode.
- Trial name
- HARMONY (NCT00888264)
- Where
- 45 sites in Belgium
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Bipolar Depression
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
The main goal of this study is to help answer the following research question(s) and not to treat the child's illness. Can this study drug make children with bipolar depression feel better? Does this study drug work better than a…
- Trial name
- NCT00844857
- Testing
- Olanzapine Fluoxetine Combination (OFC)
- Where
- 7 sites in United States, Russia
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Depressive Symptoms, Major Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology
The primary aim of this pilot study is to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for symptoms of…
- Conditions
- Depressive Symptoms, Major Depressive Disorder, Depression, Cardiology
- Trial name
- NCT05461599
- Testing
- SparkRx Mobile App
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Limbix Health, Inc.
Depressive Disorder
Safety and Efficacy Study in Patients With Major Depressive Disorder
The purpose of this study is to test if GSK163090 can reduce the symptoms of depression. The safety and how well the body can handle the drug will also be investigated.
- Trial name
- NCT00896363
- Testing
- GSK163090 1 mg, GSK163090 3 mg
- Where
- 15 sites in Russia
- Volunteers
- 99 people
- Sponsor
- GlaxoSmithKline